TopoTarget completes the capital increase and the acquisition of Apoxis SA
TopoTarget A/S announced the completion of the acquisition of Apoxis SA with 3,598,030 shares having been issued to the vendors of Apoxis. Hereby TopoTarget gains two oncology products to its pipeline. Consistent with the growth strategy pursued by TopoTarget, the acquisition of the Swiss biotech company Apoxis SA shall consolidate two emerging European oncology companies.
The two lead oncology products being developed by Apoxis are: APO010, a human FAS-ligand protein product generated via Apoxis' MegaLigandTM proprietary protein research technology platform in Phase I, and APO866, a small molecule therapeutic inhibiting the NAD+ production.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.